Building Blocks for Scalable Patient Access
Healthcare decision makers (HCDM) play a critical role in providing patients with access to high-quality, clinically validated digital therapeutics. Given the growth of the DTx industry over the last decade and lack of frameworks defining what “good” looks like, many HCDMs have needed to develop their own methods to evaluate DTx products.
DTA’s DTx Value Assessment & Integration Guide provides HCDMs and DTx manufacturers with an initial framework to assess DTx products, their value, and impact in real-world settings. With ongoing engagement from patients, clinicians, payors, and policy makers, this Guide will continue to be updated to ensure ongoing relevance in this quickly evolving ecosystem.
コメント